ERGOMED

News

News


London, UK, 18 April 2018

Dr Jan Petracek selected as one of the winners of the 2018 DIA Inspire Award

London, UK18 April 2018: Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce that Chief Operating Officer and PrimeVigilance CEO, Dr Jan Petracek will receive the DIA Inspire Award for the EMEA Region during the upcoming DIA EuroMeeting in Basel, Switzerland 17-19 April 2018.

Dr Petracek will receive the Excellence in Service Award which is awarded to the “Member of the Year” who has consistently provided outstanding service as a DIA volunteer, and who has contributed to the advancement of DIA’s mission.

This is a notable achievement, which is a result of the many years of dedication to the advancement of global health, as well as his direct contributions to DIA.

For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in health care product development and life cycle management to exchange knowledge and collaborate in a neutral setting. DIA is an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation. Today, DIA is a worldwide organization in more than 80 countries with regional offices covering the Americas, Europe, Asia, the Middle East, and Africa.

If you are attending the DIA EuroMeeting 2018 in Basel, please visit our PrimeVigilance booth #43-44 to meet Dr Petracek and the rest of the team.

 

Enquiries:

Ergomed plc Tel: +44 (0)1483 307 920
Dr Jan Petracek (Chief Operating Officer)
Consilium Strategic Communications – for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com
MC Services – for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke

 

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed’s fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed has established a portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com


|

Translate »